In-vitro Fertilization Outcomes in Females of Advanced Maternal Age with Polycystic Ovarian Syndrome
European Medical Specialist Review · 20.11.2026
DOI: 10.67452/emsr.2026.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Medical Specialist Review, online erschienen am 20.11.2026. Verfasst von Sharona Falzon und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Fertility and assisted reproductive technology (ART) is a fast-growing sub-speciality within Obstetrics and Gynaecology. After the age of thirty-five years, females experience an almost linear decrease in fertility, but in the case of polycystic ovarian syndrome (PCOS) there may be an exception to this rule. Anti-Mullerian hormone (AMH) is a hormone secreted by the granulosa cells which are proliferating in growing follicles and its serum levels as well as antral follicle count on ultrasound are both reliable markers of ovarian reserve. Age-related infertility in women is mainly linked to changes in the ovarian reserve, defined as the quality and number of remaining follicles within the ovaries at a particular age. Both AMH and antral follicle count show a decline with increasing age in normo-ovulatory women, but this kind of age-related decrease is slowed down in patients with PCOS1. PCOS is an endocrine disorder which affects up to 10% of women of reproductive-age and it accounts for up to 25% of infertility among couples1. It is characterized by infrequent ovulation, hyperandrogenism, insulin resistance and a characteristic ultrasonographic ovarian appearance with a high number of antral follicles. This ovarian dysfunction has previously been linked to infertility, but emerging studies suggest that women of advanced maternal age with PCOS display increased follicle and oocyte count during ovarian stimulation and oocyte retrieval during In Vitro Fertilization (IVF)2. Due to the increased antral follicle count in these patients, one would predict increased oocyte counts, increased number of embryos and higher incidence of pregnancy and live birth rates when compared to age-matched eumenorrheic females3. Some studies suggest that irrespective of increased oocyte yield, fertility outcomes may not vary and that there might be no extension of the reproductive window in PCOS. One must note that if oocyte yield is proven to be increased but live birth rates remain unchanged, there is limited advantage from this variation1. Despite potential increase in pregnancy rates, one must also take into consideration that PCOS is associated with increased rates of miscarriage, pre-eclampsia, gestational diabetes, preterm delivery and stillbirth4,5.
Zitieren
APA
Falzon, S., Sant, M., Portelli, J., Spiteri, L., & Falzon, C. (2026). In-vitro Fertilization Outcomes in Females of Advanced Maternal Age with Polycystic Ovarian Syndrome. European Medical Specialist Review. https://doi.org/10.67452/emsr.2026.017
Vancouver
Falzon S, Sant M, Portelli J, Spiteri L, Falzon C. In-vitro Fertilization Outcomes in Females of Advanced Maternal Age with Polycystic Ovarian Syndrome. European Medical Specialist Review. 2026. doi:10.67452/emsr.2026.017
BibTeX
@article{Falzon2026,
author = {Falzon, Sharona and Sant, Mark and Portelli, Jonathan and Spiteri, Lorella and Falzon, Chanice},
title = {In-vitro Fertilization Outcomes in Females of Advanced Maternal Age with Polycystic Ovarian Syndrome},
journal = {European Medical Specialist Review},
year = {2026},
doi = {10.67452/emsr.2026.017}
}
EUVIMED